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Caldesmon is a cytoskeleton-associated protein which
has not yet been related to neoplastic angiogenesis. In
this study we investigated the expression of the
caldesmon gene (CALD1) splicing variants and the
protein expression level in glioma microvessels ver-
sus normal brain microvasculature. To exclude
sources of splice variant expression from non-vascu-
lar components all possible cellular components
present in control and glioma samples were pre-
screened by laser-capture microdissection followed
by RT-PCR before the cohort study. We discovered
differential expression of the splicing variants of
CALD1 in the tumor microvessels in contrast to nor-
mal brain microvasculature. Missplicing of exons 1, 1
 4, and 1  4 of the gene is exclusively found in
glioma microvessels. To exclude the possibility that
this missplicing results from splice-site mutations,
mutation scanning was performed by a coupled in
vitro transcription/translation assay (IVTT). No pre-
mature stop mutations were traced by the IVTT. The
transcriptional changes consequently resulted in up-
regulation at the protein expression level. The up-regu-
lated expression of caldesmon was coincident with the
down-regulated expression of tight junction proteins
(occludin and ZO-1). The results support the notion that
missplicing of the CALD1 gene in glioma microvascula-
ture is an independent epigenetic event regulated at the
transcriptional level. The event coexists with tight junc-
tion (TJ) breakdown of the endothelial cells in glioma
microvasculature. The data reveal a novel mechanism
contributing to dysfunctionality of glioma neovascular-
ization. (Am J Pathol 2004, 164:2217–2228)
Genome-wide analyses have revealed that 40 to 60% of
human genes undergo alternative splicing.1 Alternative
splicing, therefore, seems to contribute considerably to
enable the highly complex and diverse functions en-
coded by the human genome. Alternative splicing per-
mits vertebrate pre-mRNA to be processed into multiple
mRNAs differing in their precise combination of exon
sequences, resulting in the encoding of different protein
isoforms.2 Multiple modes of alternative splicing exist,
such as alternative 5 or 3splice-site usage, differential
inclusion or skipping of particular exons, mutually exclu-
sion of exons, and more.3 Importantly, alternative splicing
is often tightly regulated in a cell type- or developmental
stage-specific mode.3 The essential nature of this pro-
cess is underscored by the fact that misregulation (mis-
splicing events) is often related to human disease.4–6
The caldesmon gene (CALD1) is a single gene with tran-
scriptional variance characterized by the recombination
of different alternative splicing modes regulated by spe-
cific promoter activities.7 The human CALD1 shares com-
mon structural and expressional properties through
mammals.8,9 The gene is located on chromosome 7q33–
34, consists of at least 15 exons and gives rise to two
major classes of protein isoforms, ie, high molecular
weight caldesmon (120 to 150 kd, h-CaD) and low mo-
lecular weight caldesmon (70 to 80 kd, l-CaD).7,10 The
conserved regions of all isoforms encoded by exon 2, 3a,
and 5 to 15 contain caldesmons’ capacity to bind to actin,
tropomyosin, Ca (2)-calmodulin, myosin, and phospho-
lipids.11 The exons 1, 3b, and 4 are alternatively spliced.
Exon 3b encodes the central  helix which is absent from
l-CaD. h-CaD isoforms are restricted to fully differentiated
smooth muscle cells (SMCs) and regulate the smooth
muscle tone. l-CaD consists of at least four splicing vari-
ants (WI-38 l-CaDs I and II, Hela l-CaDs I and II) which
are expressed via differential inclusion of the variable
alternative spliced exons 1, 1 and 4 of the gene.7 The
exons 1 and 1 encode the short amino terminus specific
for Hela l-CaDs and WI-38 l-CaDs or h-CaD, respective-
ly.7 The l-CaD isoforms are ubiquitously distributed in
various cells and dedifferentiated SMCs. They play roles
in the regulation of cell contractility, adhesion-dependent
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signaling, and cytoskeletal organization, influencing
granule movement, hormone secretion, and reorganiza-
tion of microfilaments during mitosis via mitosis-specific
phosphorylation by cdc2 protein kinase.10–12 The distinct
functions of different cell types must involve different
isoforms of caldesmon. However, the expression of the
various CALD1 splicing variants and protein isoforms has
only been investigated in a limited selection of normal
human tissues.8 In human aorta, all splicing variants of
the gene have been investigated. The expression was
restricted to h-CaD (exon 1, 3b, and 4) and WI-38 l-CaD
II (exon 1).8
In glioma, microvascular proliferation or hyperplasia is
a notorious event. Microvascular architecture and density
in low-grade gliomas are similar to that in normal brain
tissue. In anaplastic gliomas and glioblastomas however,
microvascular hyperplasia such as glomeruloid and
branching or sprouting proliferation, is a common event.
Leakage of these vessels leads to perivascular edema
and shows in neuroradiologic presentations of high-
grade gliomas. The proliferated or hyperplastic vessels
are dysfunctional in that there is a disruption of the blood-
brain barrier.
In a previous study we found the low molecular isoform
of caldesmon (l-CaD) in the cerebrospinal fluid (CSF) of
glioma patients.13 It was noticed by immunohistochem-
istry on tissue sections of the very gliomas that the ex-
pression of caldesmon was restricted to the blood ves-
sels while no immunopositivity was obtained in glial cells.
In the present study, we further investigated the CALD1
splicing variants, focusing on l-CaD in tissue samples of
68 patients with gliomas. In order to localize the caldes-
mon protein in the tumors, immunohistochemistry was
performed on tissue sections of the gliomas of the same
patients from whom the CSF samples were used. The
expression of caldesmon appeared to be restricted to the
blood vessels and was not seen in glial cells. In addition,
any possible or minor cellular components present in the
normal controls and glioma samples were pre-screened
by LCM/RT-PCR and immunohistochemistry. Missplic-
ings in glioma microvessels are revealed by RT-PCR. The
transcriptional changes consequently result in an up-
regulated protein expression level. Alterations of splicing
patterns could result from splice-site mutations via acti-
vation of cryptic splice-site usage.16,17 The phenotypic
effects of such mutations on mRNA splicing often cause
codon frame-shifts or single base substitution conse-
quently resulting in premature termination codons.18,19
Such splice-site mutations account for at least 15% of
point mutations causing disease in humans.16,20 To rule
out the presence of splice-site mutations resulting in the
missplicing events of the CALD1 gene in our tumor cases,
the samples were scanned by coupled in vitro transcrip-
tion/translation assay (IVTT, also known as the protein
truncation test (PTT)). The principle of IVTT is based on
targeting mutations that generate truncated proteins in-
duced by premature translation termination.21 IVTT en-
ables to pinpoint the site of a mutation, offers good sen-
sitivity, and a low false-positive rate.22 Further tight
junction proteins (occludin and ZO-1) were co-investi-
gated in this study. Interestingly, the up-regulated ex-
pression of l-CaD resulting from CALD1 missplicing was
coincident with the down-regulation of occludin and
ZO-1, causing tight junction (TJ) breakdown of the endo-
thelial cells in glioma microvasculature.
Materials and Methods
Samples and Histology
The study was conducted on 68 snap-frozen specimens
of glioma stored in the archives of the Department of
Pathology, Erasmus Medical Center, Rotterdam, the
Netherlands. Histopathological typing and grading of the
tumors was performed on the corresponding paraffin
sections based on the latest World Health Organization
classification of tumors of the central nervous system.23
Frozen section screening was to get rid of those samples
with massive necrosis, hemorrhage, and contaminating
normal tissues. Finally, the tumors analyzed included 26
glioblastomas, 23 oligodendrogliomas (among which 18
anaplastic oligodendrogliomas), and 19 pilocytic astro-
cytomas. Six samples of white matter obtained from pa-
tients without neurological or systemic disease served as
controls.
Light Microscopy/Immunohistochemistry
To determine the site and distribution of the l-CaD protein
expression in the tumors and control samples, tissue
sections were immunohistochemically stained with a
monoclonal anti-l-CaD antibody at a 1:40 dilution (BD
Biosciences). The immunohistochemical procedure was
described previously.13
Pre-Screening CALD1 Expression in All of the
Cellular Components Possibly Present in the
Tissue Samples Used by Laser-Capture
Micodissection (LCM)/RT-PCR and
Immunohistochemistry
The main purpose for the pre-screening experiments was
to determine whether unfractional samples can be used
for analysis. The white matter controls predominantly
consist of glial cells and blood vessels with minor blood
cell components. In glioma, the major cellular compo-
nents are neoplastic glial cells (glioma cells) and hyper-
plastic or proliferated microvessels with possible or minor
contaminating cells such as inflammatory cells, fibro-
blasts, and leptomeningeal cells. Normal glial cells and
normal vessels were captured from the control samples
(4 cases), while glioma cells and glioma vessels were
captured from glioma cases (10 cases), respectively.
Fibroblasts and leptomeningeal cells were captured from
normal dura and arachnoid (two each from autopsy
cases), respectively. Since all kinds of inflammatory cells
are derived from transmigration of leukocytes from blood
vessels into the brain tissue, 20 normal blood samples
were used for screening of possible CALD1 expression in
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leukocytes. LCM was performed by using a Robot Mi-
crobeam laser microscope as the manufacturer in-
structed (P.A.L.M, Microlaser Technologies, Bernried,
Germany). Frozen sections for LCM were prepared by
using Rnase-free conditions. The used frozen tissue
blocks were sectioned at 5 m in cryostat, mounted on
non-coated clean glass sliders, and stored at80°C until
use. The staining procedures of the sections were mainly
based on the published protocol at http://pathbox.wus-
tl.edu/tisscore/protocols.htm.24 A slight modification of
the protocol was made by skipping “automation buffer”
and using the stainer (HisGene, Arcturus) instead of May-
er’s hemotoxylin and eosin. For Robot Microbeam laser
microdissection, the tissue area of interest was selected
and positioned (Figure 1, A, C, and E), and cut out using
a focused, pulsed laser beam. The dissected areas were
collected in the cap of a microcentrifuge tube containing
18 l Trizol (Invitrogen) via laser pressure catapulting.
The object of interest was catapulted off the slide using a
high-energy, defocused, short-duration laser pulse (Fig-
ure 1, B, D, and F). The cap with the procured tissues was
immediately placed on a microcentrifuge tube containing
200 l Trizol (Invitrogen) and lysed by mixing for further
RNA isolation.
CALD1 Transcript Analysis
Total cellular RNA was extracted from the selected spec-
imens using Trizol per the manufacturer’s protocol (In-
vitrogen). First-strand complementary DNA (cDNA) was
generated with an oligo (dT)23 primer and DuraScript
reverse transcriptase (Sigma). The resulting cDNA was
amplified by PCR using CALD1 specific primer sets span-
ning the splice sites of this gene toward all of the four
splicing variants of l-CaD as described elsewhere.7 A
primer set for the CALD1, designed to amplify all of the
splicing variants,25 was used for initial examining the
microdissected samples (the product size for l-CaD iso-
forms is 744 bp). Glyceraldehyde 3-phosphate dehydro-
genase (GAPD) fragment26 was prepared by PCR as an
internal control. All of the primers used in this study were
commercially synthesized (Invitrogen). The amount of
each RNA sample used was selected on the basis of
identical amounts of GAPD cDNA amplified from each
sample. At a 2-minute initial denaturation at 94°C, ampli-
fication conditions were as follows: 94°C for 15 seconds,
66°C (60°C for GAPD) for 30 seconds and 68°C for 1
minute for 36 cycles (40 cycles for the microdissected
samples), and final extension at 68°C for 5 minutes.
GAPD transcripts were amplified by 30 cycles (36 cycles
for the microdissected samples). Negative controls, con-
sisting of one sample without reverse transcriptase and
one without template, were included in each experiment.
The PCR products were resolved by electrophoresis on a
1% agarose gel containing ethidium bromide, and
viewed under ultraviolet illumination. At least three exper-
iments were performed for reproducibility.
Immunoblotting
Total cellular protein was co-isolated and lysed during
RNA isolation by Trizol according to the manufacturer’s
protocol (Invitrogen). Protein concentrations in the ex-
tracts were determined by the BCA protein assay (Pierce
Chemical Co). Protein samples (15 g/lane) were sepa-
rated on a 12% SDS-polyacrylamide gel and transferred
to nitrocellulose. Electroblotting was performed on a ni-
trocellulose membrane in 25 mmol/L Tris and 192 mmol/L
glycine containing 20% methanol. The membrane was
then pre-treated with 5% skim milk in Tris-buffered saline
with Tween (TBST) overnight at 4°C. The membrane was
incubated with monoclonal anti-l-CaD antibody (BD Bio-
sciences, dilution 1:1000) in TBST or anti-,-tubulin
cocktail (Lab Vision, dilution 1:1000) in TBST for 1 hour at
room temperature. The membrane was further incubated
with horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG antibody (Zymed Laboratory Inc., dilution
1:10,000) for 1 hour at room temperature. The peroxidase
was finally activated with enhanced chemiluminescence
(ECL kit, Amersham) and the immunoreactivity was visu-
alized with Kodak X-Omat AR X-ray film. For quantitative
analysis of l-CaD, the bands on films were scanned by
using a UMAX PowerLook II scanner (Genomic Solutions,
Huntingdon, UK) at 750 dpi. Densitometric analysis was
performed with the ONE-Dscan software (Scanalytics,
Figure 1. Laser-capture microdissection of glial cells and vessels. A: The
target normal glial cell population was dissected with ultraviolet laser. B: The
dissected cells were photo-ablated within the laser focus and then directly
collected into a microcentrifuge tube cap filled with Trizol for RNA isolation
by laser pressure catapulting. C: The target tumor cell population (glioblas-
toma) was dissected with ultraviolet laser. D: The dissected cells were
photo-ablated and collected as mentioned under B. E: The targeted hyper-
plastic vessel in pilocytic astrocytoma was positioned. F: The dissected vessel
was photo-ablated and collected as mentioned in (B).
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Billerica). Each experiment was repeated at least twice.
The average change in band intensities was normalized
against tubulin.
IVTT
The specimens used by a coupled in vitro transcription/
translation assay (IVTT) were pre-treated by puromycin
(200 g/ml) (Sigma) for 6 hours at room temperature
before RNA isolation. Puromycin is a translation inhibitor
known to suppress nonsense-mediated mRNA decay
(NMD), thus allowing mutation screening at the RNA lev-
el.27 The PCR products suitable for IVTT analysis were
generated with sense primers containing a T7 RNA poly-
merase promoter, a start condon, and the Kozak trans-
lation initiation sequence.28 The transcripts were ampli-
fied by 40 cycles. Since the normal transcripts containing
exons 1, 1  4, and 1  4 were not detected in the
control white matter, the corresponding transcripts used
in IVTT were retrieved from normal stomach, prostate,
and thyroid, respectively. The PCR product (2.5 l) am-
plified from each transcript was incubated in the TNT/T7
non-radioactive coupled transcription and translation
system (TNT Quick for PCR DNA, Promega) for 90 min-
utes at 30°C in a total volume of 50 l in the presence of
biotinylated lysine residues. The biotinylated lysine resi-
dues are incorporated into nascent protein during trans-
lation, eliminating the need for labeling with [35S] methi-
onine or other radioactive amino acids, and allowing
non-radioactive detection of protein synthesized in vitro
by binding either streptavidin-alkaline phosphatase
(streptavidin-AP) or streptavidin-horseradish peroxidase
(streptavidin-HRP). In our experiments, the in vitro syn-
thesized proteins were size-fractionated on 12% SDS-
polyacrylamide mini-gels. The fractionated proteins were
electroblotted onto nitrocellulose at a constant voltage of
100V for 60 minutes. Streptavidin-HRP binding (dilution
1:20,000) was used for visualization with enhanced
chemiluminescence (ECL kit, Amersham) as the protocol
(Promega).




Cryostat sections (5 m) were cut onto non-coated mi-
croscope slides (Menzel-Glaser). Slides were fixed in
100% ice-acetone at room temperature for 10 minutes
and air-dried. After washes with phosphate-buffered sa-
line (PBS), indirect immunofluorescence was carried out
by using the anti-occludin polyclonal antibody (Zymed
Laboratories Inc., dilution 1:100) and anti-ZO-1 poly-
clonal antibody (Zymed Laboratories Inc., dilution 1:100)
with incubation for 1 hour at room temperature. The FITC-
conjugated swine anti-rabbit IgG (Dako, dilution 1:100)
was used for 1 hour at room temperature for visualization.
Slides were washed with PBS, mounted in imselmount
(Klinipath), and covered with Pertex and covering glass.
A CCD video camera (Leica) mounted on a Leica (DM-
RXA) fluorescence microscope was used to capture dig-
ital images on a Leica computer (Q550 CW) running the
software (Leica CW 4000 FISH Version V 1.0).
For immunohistochemistry, 5-m paraffin sections
were cut onto aminopropyltriethoxysilane (APES)-coated
glass slides (Knittel Glaser). Dewaxed sections were pre-
treated in 0.1% pronase (Sigma) for 10 minutes at 37°C.
After the pre-treatment, the slides were washed with PBS
and incubated with anti-occludin polyclonal antibody
(Zymed Laboratories Inc., dilution 1:100) for 2 hours at
room temperature. The biotinylated goat anti-rabbit
(Dako, dilution 1:200) was used for 1 hour at room tem-
perature for visualization. Again the slides were washed
in PBS and incubated with StreptABC complex/AP (Dako,
dilution 1:100) for 1 hour at room temperature. After the
slides were washed with PBS, enzyme detection was
performed by using a solution of Tris-HCl (pH 8.0) con-
taining 1% new fuchsin, 1% natriumnitriet, 0.03% napthol
AS-MX phosphate (Sigma), and 0.025% levamisol (Ac-
ros) for 1 hour at room temperature. The slides were
washed again with PBS, mounted in imselmount (Klinin-
path), and covered with Pertex and covering glass for
examination under a light microscope.
Results
Confirmation of Absent Expression of CALD1
Transcript and Protein in Glial Cells
Immunohistochemistry showed that the expression of the
caldesmon protein was restricted to the blood vessels.
The immunoreactivity for the caldesmon protein was
stronger in the hyperplastic microvessels of the gliomas
as compared to normal brain microvasculature (Figure 2,
A to E). The enhanced immunoreactivity was confirmed
by immunoblotting analysis showing a higher expression
of total l-CaD in the tumor samples (see below). At the
light microscopical level no immunopositivity was ob-
served in neoplastic and normal glial cells in the speci-
mens. Neither the neoplastic, nor the normal, glial cells
captured by LCM showed expression of CALD1 tran-
scripts, in contrast to the positive controls (tumor vessels)
(Figures 1 and 3).
Expression Profiles of CALD1 in Microdissected
Normal Brain Vessels and Other Possible or
Minor Cellular Components in Normal Controls
and Gliomas
The microdissected microvessels from the normal con-
trols showed expression of exon 1(WI-38 II) (Figure 4).
Fibroblasts express CALD1 with restriction to exon 1 and
with immunopositivity of caldesmon (Figure 5). Further,
no CALD1 expression was found in leptomeningeal cells
by LCM/RT-PCR and immunohistochemistry (Figure 6).
No CALD1 expression in leukocytes or inflammatory cells
was detected (Figure 7).
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Differential Expression of CALD1 Transcripts
and Protein in Glioma Microvessels versus
Normal Brain Microvasculature
The results of immunohistochemistry and the LCM data
revealed that there was no expression of protein and
transcript of the CALD1 gene in normal and neoplastic
glial cells. In addition, the pre-screening experiments
show that no differential expression patterns of CALD1
were detected in any of these cell types. Thus, it is
feasible to use unfractional samples of control tissue
(white matter) and glioma samples. Sixty-eight glioma
samples were assessed by RT-PCR. The transcript con-
taining exon 1 (752 bp, WI-38 l-CaD II) was invariably
detected in all tumors and control samples, while the
transcripts containing the exons 1 (731 bp, Hela l-CaD II),
1  4 (670 bp, Hela l-CaD I), and 1  4 (691 bp, WI-38
l-CaD I) were exclusively detected in the tumors (Figure 8
Figure 2. Immunohistology of a series of representative glioma subtypes and
normal control. Immunohistochemistry showed that the expression of the
protein was restricted to the blood vessels and stronger immunoreactivity was
noticed in the hyperplastic vessels of the gliomas. No immunopositivity was
obtained in normal glial cells and their neoplastic counterparts. A: Immuno-
positivity for l-CaD is observed in the normal blood vessels in control white
matter (magnification, 250). B: Immunopositivity for l-CaD is seen in the
oligodendroglioma vessels without hyperplasia (magnification, 250). C:
Strong immunopositivity for l-CaD is found in the hyperplastic microvessels in
a glioblastoma (magnification, 400). D: Strong immunopositivity for l-CaD is
seen in the hyperplastic microvessels in an anaplastic oligodendroglioma
(magnification, 250). E: Strong immunopositivity for l-CaD is noticed in the
hyperplastic microvessels in a pilocytic astrocytoma (magnification, 250).
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and Table 1). The transcript of the ubiquitously ex-
pressed housekeeping gene GAPD (540 bp) was uni-
formly amplified in all of the used samples. The splicing
patterns show various frequencies and combinations of
the expressed transcripts (Table 1). The expression pat-
tern of l-CaD in normal brain vessels is similar to that of
the human normal aorta cDNA.8 The expression of the
additional transcripts in the gliomas appears to be tightly
linked with the presence of microvascular hyperplasia or
proliferation in the sample examined. The samples with
normal-looking microvessels retained normal expression
patterns of CALD1. The findings in the microdissected ves-
sels (4 of 6 controls and 10 of 68 gliomas) further confirmed
the results from these unfractional samples. To determine
whether the change in l-CaD transcription would be mani-
fested as changes in the protein quantity, immunoblotting
analysis was performed on total cell lysates of the glioma
and control samples. Densitometric analysis revealed an
average 3.6-fold enhancement of caldesmon protein levels
in the tumor samples as compared to the normal controls
(Figure 9), indicating that the transcriptional changes were
translated into altered protein levels.
Splice-Site Mutation Scanning
Mutation screening was carried out on 20 glioma cases
by applying the IVTT to exon 1, exon 1, and exon 4,
spanning all splice sites for each transcript. No mutations
leading to premature protein terminations were observed
in these target exons (Figure 10).
Tight Junction Breakdown in Glioma
Microvasculature
The expression of TJ proteins (occludin and ZO-1) was
detected by immunohistochemistry (IH) and immunoflu-
Figure 3. Analysis of CALD1 transcript expression in purified glial cells by
LCM. The used primer set was designed to amplify all of the splicing variants.
Lane 1 represents the positive control (tumor vessels; Figure 1, E and F)
showing CALD1 transcript expression (744 bp). Lane 2 (normal glial cells)
and lane 3 (neoplastic glial cells) show no expression of CALD1 transcripts.
The housekeeping gene (GAPD) was identically amplified in all of the
samples.
Figure 4. Laser-capture microdissection of normal brain vessels. A: Normal brain vessels before microdisection. B: The target vessels from A after microdissection.
C: The RT-PCR results from the microdissected vessels. These normal vessels express exon 1 only.
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orescence (IF). Occludin and ZO-1 in our study showed
similar expression patterns (data from ZO-1 not shown).
In longitudinally sectioned normal blood vessels, the
staining patterns for occludin and ZO-1 were predomi-
nantly axial and linear, with occasional anastomoses/
bifurcations (Figure 11, A1 and A2). In transversely sec-
tioned vessels, however, the staining revealed short,
radial or near-radial, continuous staining bands (Figure
11, B1 and B2). In the proliferated and/or hyperplastic
glioma microvessels abnormalities in expression of oc-
cludin and ZO1 were observed. The abnormalities in-
clude reduced clarity of TJ bands (Figure 11, C1 and C2),
interruption or discontinuity (Figure 11, D1 and D2),
beading or spot-like pattern of the TJ staining (Figure
11E), or diffuse intracytoplasmic staining or absence or
complete loss of immunostaining (Figure 11F).
Figure 5. Laser-capture microdissection of fibroblasts from normal dura. A: Normal dura before microdissection. B: The microdissected target cell population from
A. C: Positive immunoreactivity for caldesmon is shown in the fibroblasts. D: The RT-PCR results from the micodissected fibroblasts. The fibroblasts show CALD1
expression with restriction to exon 1.
Figure 6. Laser-capture microdissection of normal leptomeningeal cells from the arachnoid. A: Normal arachnoid before microdissection. B: The microdissected
target leptomeningeal cell population from A. C: No immunoreactivity for caldesmon is seen in the leptomeningeal cells. D: The RT-PCR results from the
micodissected leptomeningeal cells. PC, positive control; LC, leptomingeal cells. The housekeeping gene (GAPD) was identically amplified in the PC and LC. No
expression of CALD1 transcript in leptomeningeal cells was found.
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Correlation of Up-Regulation of l-CaD Resulting
from CALD1 Missplicing and TJ Breakdown in
Glioma Microvasculature
The up-regulation of l-CaD resulting from CALD1 miss-
plicing in hyperplastic glioma microvasculature is coinci-
dent with down-regulation of occludin (Figure 12) and
ZO-1. In our study, strong immunopositivity of l-CaD in
hyperplastic glioma microvasculature was always con-
comitant with complete or near-complete loss of occludin
and ZO-1 expression.
Discussion
Tumor vessels are morphologically and functionally dif-
ferent from normal vasculature.29 The endothelial cells
are mitotically active and there is enhanced permeability
of the micovascular walls.30 Nevertheless, there is sub-
stantial difference in neoplastic angiogenesis between
tumor types, depending on the organ system involved
and differential expression of cytokines by organ-specific
stroma.31,32 In the brain, the microvascular system is
composed of endothelial cells surrounded by a layer of
pericytes.33 The lack of smooth muscle cells in brain
tissue suggests that any contractile activity must be per-
formed by either endothelial cells, pericytes, or both. The
development of glioma microvasculature may serve as a
typical model of neoplastic angiogenesis. In particular,
glioblastoma are among the best-vascularized tumors in
humans with highest endothelial cell proliferation indi-
ces.23,32 Numerous factors such as angiopoietins and
their Tie receptors,34 PDGF-B,35 monocyte chemotactic
protein 1,36 ephrins, and Eph-B receptors37,38 are likely
candidates for the activation of various modes of angio-
genesis, and mediation of endothelial-endothelial and
endothelial-pericyte interactions in the adaptation to
physiological and pathological stimuli.39 So far, the
caldesmon protein has not yet been implicated in angio-
genesis.
Caldesmon is an actomyosin-associated cytoskeletal
protein residing in contractile microfilaments (MFs).10
The actin cytoskeleton in eukaryotic cells operates as a
tension-sensing molecular device and has an important
regulatory role on cellular contractility and adhesion-de-
pendent signaling via caldesmon modulation.40 The con-
tractile functions are carried out by modulating cellular
tensional integrity (tensegrity) without disrupting the cel-
Figure 7. Examination of CALD1 expression in leukocytes or inflammatory
cells. A representative RT-PCR result of the blood samples is shown. PC,
positive control; B1 to B6, blood samples examined. The housekeeping gene
(GAPD) was identically amplified in all of the samples examined. No CALD1
expression was found in the leukocytes or inflammatory cells.
Figure 8. Analysis of CALD1 splicing transcripts. Total RNA was isolated
from the tumors and controls, and subjected to RT-PCR analysis. The ex-
pressed transcript variants and the corresponding sizes are indicated on the
left and right, respectively. Each lane was labeled as W (white matter), T1
(glioblastoma), T2 (anaplastic oligodendroglioma), and T3 (pilocytic astro-
cytoma), respectively. The housekeeping gene (GAPD) was identically am-
plified in all samples. The transcript containing exon 1 is invariably co-
detected in the control and tumors, while the transcripts containing exon 1,
1  4, and 1  4 are exclusively expressed in the tumor samples.
Figure 9. Immunoblotting analysis of l-CaD. The labels of the consecutive
lanes correspond to those in Figure 8. Enhanced l-CaD protein expression is
revealed in the tumors as compared to the control. Tubulin expression was
used as a total protein loading control. The average change in band inten-
sities was normalized against tubulin signal.




Hela II (exon 1) WI-38 II (exon 1) Hela I (exon 1  4) WI-38 I (exon 1  4)
Controls 
1–8 Glioblastoma    
9–17 Glioblastoma   
18–26 Glioblastoma  
27–32 Anaplastic oligodendroglioma    
33–34 Anaplastic oligodendroglioma   
35–38 Anaplastic oligodendroglioma   
39–40 Oligodendroglioma   
41 Oligodendroglioma  
42–47 Anaplastic oligodendroglioma  
48–49 Oligodendroglioma 
50–56 Pilocytic astrocytoma    
57–58 Pilocytic astrocytoma   
59–61 Pilocytic astrocytoma  
62–63 Pilocytic astrocytoma  
64–68 Pilocytic astrocytoma 
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lular structural integrity.41 However, alterations of CALD1
expression and the molecular mechanisms leading to
such alterations in the context of neoplastic angiogenesis
remain unexplored. Based on our previous findings,13 we
hypothesized that the enhanced protein expression in
glioma cases is regulated at the transcriptional level, not
just simply reflecting post-translational modifications of
the protein. Definitely, the analysis of transcriptional
changes could potentially lead to the identification of
novel transcription-dependent and -independent molec-
ular contributors to the process of neoplastic neovascu-
larization. To address this issue, we investigated the
CALD1 splicing transcripts and expression level of this
protein. Our data indicate that the transcriptional
changes of CALD1 in splicing variants are translated into
altered protein levels, and both the expression of the
splicing variants and the protein are up-regulated during
the process of neo-angiogenesis in gliomas. In non-mus-
cle cells, simulation of CALD1 overexpression by trans-
fection of full-length l-CaD results in the inhibition of cell
contractility and interferes with Rho A-mediated formation
of stress fibers and focal adhesions.40 The co-activated
caldesmon isoforms induce an overexpression of the
protein and could have a synergetic effect on the cellular
contractility of the vascular components, enhancing the
permeability of microvessels, and consequently facilitate
the extravasation and migration of cancer cells. More-
over, both an increase in cellular calcium concentration
and caldesmon phosphorylation cause dissociation of
Figure 10. Scanning of splice-site mutations. The four panels show the IVTT
analysis of the representative cases corresponding to Figures 8 and 9. The
wild polypeptides synthesized in vitro contain exon 1 from white matter
indicated as “W” (A), exon 1 from stomach indicated as “S” (B), exon 1  4
from prostate indicated as “P” (C) and exon 1  4 from thyroid indicated as
“T” (D). The predicted MWs of these polypeptides are indicated in kd. No
truncated polypeptides are observed in the glioma cases as compared to the
controls. D displays a mass heterogeneity by two bands. This mass hetero-
geneity is possibly caused by the inclusion or exclusion of exon 4, or
alternatively, by an internal ATG initiation site.
Figure 11. Immunofluorescence (IF) and immunohistochemical (IH) staining of occludin. A1, B1, C1, D1, and E show IH images, while A2, B2, C2, D2, and
F exhibit IF images. A1 and A2: Immunoreactive pattern for occludin in a longitudinal section of normal brain vessels (magnification, 250). The vessels show
an axial and linear staining pattern with occasional anastomoses or bifurcations. B1 and B2: Immunoreactive pattern for occludin in a transverse section of normal
brain vessels, characterized by short, radial or near-radial, continuous staining bands (magnification, 250). C1 and C2: Hyperplastic glioma vessels immuno-
stained for occludin, showing reduced clarity of TJ patterns (magnification, C1100; C2250). D1 and D2: Discontinous immunostaining for occludin in a glioma
vessel (arrows) (magnification, 250). E: Glioma vessel with spot-like or beading immunostaining pattern for occludin (arrows) (magnification, 250). F:
Redistribution of occludin immunoreactivity in the endothelial cytoplasm (arrows) and complete loss of occludin staining (arrowheads) (magnification, 400).
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caldesmon from actin and results in weakening most of
caldesmon’s properties.10 Thus, it seems that caldesmon
carries out a regulatory role in endothelial cell spread and
elongation, two properties related to vascular develop-
ment.42–44 There is evidence from in vitro experiments
that the expression of CALD1 both at the transcriptional
and translational level was markedly and reproducibly
down-regulated during vascular tube formation.45 Taken
together, caldesmon appears to be a target in a variety of
signaling pathways that modulate its function and
thereby its effect on cell contractility and adhesion-de-
pendent signaling.40
Alternative splicing of specific pre-mRNAs is con-
trolled by cis-acting regulatory elements (exonic splicing
enhancers) and trans-acting factors (SR proteins).3 The
alternative exons are commonly weakened as compared
to constitutive exons by having suboptimal splice sites
and length but are strengthened by the presence of exon
enhancers that bind to putative splicing regulators46
and/or activation of cryptic splice sites by mutation.16 We
did not trace any splice-site mutations in the examined
cases. It appears that an alternative mechanism may
alter the interaction between an exonic splice enhancer
and mRNA splicing factors of the CALD1 via a signaling
pathway modifying the splicing apparatus.2,47,48 The reg-
ulation of the transcriptional activation of CALD1 splicing
variants could have far-reaching epigenetic effects on
the development of molecular targeted anti-angiogenic
therapies.
The tight junction is the most apical located element of
the junctional complex in epithelial and endothelial
cells.49 The TJ between endothelial cells of brain capil-
laries form the structural basis of the blood-brain barrier
(BBB), which controls the exchange of molecules be-
tween blood and CNS. The endothelial cells of the normal
blood-brain barrier possess tight junctions that maintain a
severely restricted permeability. In the hyperplastic gli-
oma microvasculature morphological alterations such as
fenestrations, the increase of caveolae, pericyte detach-
ment, and thickening and alteration of the extracellular
matrix (ECM) exist.50–52 These changes result in a dra-
matic increase of the permeability of these vessels. Oc-
cudin and ZO-1 are well-studied TJ proteins. In particu-
lar, occludin was the first identified transmembrane
protein that is exclusively localized at TJ.53 Therefore,
occludin is considered a sensitive and reliable marker of
TJs.54 The inverse relationship between the regulation of
l-CaD and occludin or ZO-1 found in our study has not yet
been reported so far. Our data clearly reveal the up-
regulation of l-CaD resulting from CALD1 missplicing in
hyperplastic glioma microvessels with a concomitant loss
of TJ integrity of the endothelial cells. Although the mo-
Figure 12. Up-regulation of l-CaD resulting from CALD1 missplicing coincident with down-regulation of occludin. A: A glioblastoma with expression of four
splice variants of CALD1 (Case 6, Table 1). The strong immunoreactivity of l-CaD is observed (magnification, 250). B: An adjacent section from A was
immunostained for occludin. Complete loss of occludin immunoreactivity is observed (magnification,250). C: An anaplastic oligodendroglioma with expression
of four splice variants of CALD1 (Case 28, Table 1). Strong immunoreactivity of l-CaD is noticed in this section (magnification, 250). D: An adjacent section
immunostained for occludin. Near-complete loss of occludin expression is observed (magnification, 250). In addition, the occludin redistribution in endothelial
cytoplasm and ingestion by glial cells are shown.
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lecular basis for this correlation remains unclear, our data
are indicative of a specific contribution of CALD1 expres-
sion patterns to glioma angiogenesis and generate hy-
potheses regarding the mechanisms contributing to the
dysfunctionality of glioma neovascularization.
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